News

GSK picks up asthma mAb
Enlarge image

R&DUKIreland

GSK picks up asthma mAb

29.07.2016 - GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.

CNTO 7160 prevents interleukin-33 from binding to the ST2 receptor (IL-33R). This pathway is considered to be a promising target for the treatment of asthma. Promising enough that British pharma major GlaxoSmithKline is paying £175m (€208m) up front to Janssen Sciences Ireland UC for the exclusive, worldwide license. 

“The IL-33 receptor antibody joins our diverse respiratory R&D portfolio of targeted biological therapies and offers the potential to block a fundamental driver of the disease,” said Dave Allen, Head of Respiratory R&D at GSK.

Under the terms of the agreement, GSK will assume all development, manufacturing and commercialisation activities worldwide with the exception of the ongoing phase I study, which Janssen will continue to run through to completion. Janssen will receive up to £175 million comprising an upfront payment, development and first commercial sales milestones, in addition to tiered royalties on sales and further considerations contingent on future sales performance.

Allen added: “Following our recent successful launch of a first-in-class biologic for severe asthma in an eosinophilic population, we plan to investigate this asset’s potential to treat other targeted populations, for which there are currently no effective medicines.”

© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2016-03/gsk-picks-up-asthma-mab.html

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/news/news.html?sort=asc&cHash=12816a46393f66f5eba2124c4ccf3dc7

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ZEALAND PHARMA (DK)131.00 DKK10.08%
  • DIAMYD MEDICAL -B- (S)4.69 SEK8.56%
  • IPSEN (F)59.44 EUR6.68%

FLOP

  • MOLOGEN (D)2.05 EUR-10.87%
  • PHARMING (NL)0.22 EUR-8.33%
  • VALNEVA (F)2.40 EUR-4.38%

TOP

  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)55.41 USD50.8%
  • VERNALIS (UK)44.50 GBP35.9%

FLOP

  • MOLOGEN (D)2.05 EUR-30.5%
  • SANTHERA (CH)55.00 CHF-26.8%
  • NICOX (F)10.49 EUR-14.3%

TOP

  • KARO BIO (S)31.20 SEK1874.7%
  • NICOX (F)10.49 EUR455.0%
  • SAREUM HOLDINGS (UK)0.77 GBP234.8%

FLOP

  • BB BIOTECH (D)44.84 EUR-84.7%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.78 SEK-78.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 28.07.2016